Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cavion LLC
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Jazz’s $312.5m acquisition will add to the company’s pipeline of products in neurological conditions, but only at the Phase-II stage.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
- Other Names / Subsidiaries
- Tau Therapeutics LLC
- Xdynia LLC